This is similar to its reported efficacy for SMARCA4 mutated lung cancers reported by Deribe et al. (2018)63, suggesting oxidative phosphorylation inhibitors generally have potential for treatment of SWI/SNF depleted tumors. Here, SMARCA4 is linked to lung cancer.